[
    [
        {
            "time": "2021-04-15",
            "original_text": "COVID-19 cases keep surging in some U.S. states, and Michigan governor continues plea for more vaccines as shots in arms hits daily record",
            "features": {
                "keywords": [
                    "COVID-19",
                    "cases",
                    "surging",
                    "vaccines",
                    "record"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "COVID-19 cases keep surging in some U.S. states, and Michigan governor continues plea for more vaccines as shots in arms hits daily record",
                "Correlation": 4,
                "Sentiment": 3,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-15",
            "original_text": "Lilly says U.S. government modified purchases of its COVID-19 antibody treatments",
            "features": {
                "keywords": [
                    "Lilly",
                    "U.S.",
                    "government",
                    "modified",
                    "purchases",
                    "antibody",
                    "treatments"
                ],
                "sentiment_score": 0.2,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly says U.S. government modified purchases of its COVID-19 antibody treatments",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-15",
            "original_text": "The Zacks Analyst Blog Highlights: Oracle, Eli Lilly and BP",
            "features": {
                "keywords": [
                    "Zacks",
                    "Analyst",
                    "Blog",
                    "Oracle",
                    "Eli Lilly",
                    "BP"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "technology",
                    "healthcare",
                    "energy"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: Oracle, Eli Lilly and BP",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 2,
                "Impact": 2,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-15",
            "original_text": "UPDATE 1-Eli Lilly to focus on selling COVID-19 antibody drug combination",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "focus",
                    "selling",
                    "COVID-19",
                    "antibody",
                    "drug",
                    "combination"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "UPDATE 1-Eli Lilly to focus on selling COVID-19 antibody drug combination",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-15",
            "original_text": "Eli Lilly ends supply agreement with U.S. govt for COVID-19 antibody drug",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "ends",
                    "supply",
                    "agreement",
                    "U.S.",
                    "govt",
                    "COVID-19",
                    "antibody",
                    "drug"
                ],
                "sentiment_score": -0.5,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Eli Lilly ends supply agreement with U.S. govt for COVID-19 antibody drug",
                "Correlation": 10,
                "Sentiment": 4,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-04-15",
            "original_text": "Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together",
            "features": {
                "keywords": [
                    "Lilly",
                    "modified",
                    "COVID-19",
                    "purchase",
                    "agreement",
                    "bamlanivimab",
                    "U.S.",
                    "government",
                    "focusing",
                    "supply"
                ],
                "sentiment_score": 0.3,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly modified COVID-19 purchase agreement for bamlanivimab alone with the U.S. government and is focusing on supply of bamlanivimab and etesevimab together",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        }
    ]
]